Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 4, 2010, Pages 297-304

  Beyer, Tanja ^a   Matz, Magnus ^b   Brinz, Daniela ^a   Rädler, Oliver ^c   Wolf, Bernhard ^c   Norwig, Jochen ^d   Baumann, Knut ^b   Alban, Susanne ^e   Holzgrabe, Ulrike ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^c Ratiopharm   (Germany)

^d Federal Institute for Drugs and Medical Devices   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

Author keywords

Coagulation assay; Dermatan sulfate; NMR spectroscopy; Optical rotation; Oversulfated chondroitin sulfate; PCA; Residual solvents; Unfractionated heparin

Indexed keywords

ACETIC ACID; ACETONE; ALCOHOL; CHONDROITIN SULFATE; DERMATAN SULFATE; FORMIC ACID; GLYCOSAMINOGLYCAN; HEPARIN; METHANOL; OVERSULFATED CHONDROITIN SULFATE; UNCLASSIFIED DRUG; WATER; ANTICOAGULANT AGENT; FORMIC ACID DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; SOLVENT;

ARTICLE; DRUG CONTAMINATION; DRUG IMPURITY; DRUG STRUCTURE; GERMANY; OPTICAL ROTATION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY CONTROL; BLOOD CLOTTING; BLOOD CLOTTING TEST; CHEMISTRY; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MEDICAL LITERATURE; MEDICINAL CHEMISTRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; STANDARDS;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CHEMISTRY, PHARMACEUTICAL; CHONDROITIN SULFATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DERMATAN SULFATE; DRUG CONTAMINATION; FORMIC ACIDS; GERMANY; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; MAGNETIC RESONANCE SPECTROSCOPY; OPTICAL ROTATION; PHARMACOPOEIAS AS TOPIC; PRINCIPAL COMPONENT ANALYSIS; QUALITY CONTROL; SODIUM ACETATE; SOLVENTS; WATER; FORMATES;

EID: 77953543943     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.04.002     Document Type: Article

References (20)

1. Alban S. Carbohydrates with anticoagulant and antithrombotic properties. Carbohydrates in Drug Design 1997, 209-276. Marcel Dekker, New York. Z.J. Witczak, K.A. Nieforth (Eds.).
2. Alban S. The 'precautionary principle' as a guide for future drug development. Eur. J. Clin. Invest. 2005, 35(Suppl. I):33-44.
3. 1H nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 2008, 48:13-19.
4. Bianchini P., Liverani L., Spelta F., Mascellani G., Parma B. Variability of heparins and heterogeneity of low molecular weight heparins. Semin. Thromb. Hemost. 2007, 33:496-502.
5. Blossom D.B., Kallen A.J., Patel P.R., Elward A., Robinson L., Gao G., Langer R., Perkins K.M., Jaeger J.L., Kurkjian K.M., Jones M., Schillie S.F., Shehab N., Ketterer D., Venkataraman G., Kishimoto T.K., Shriver Z., McMahon A.W., Austen K.F., Kozlowski S., Srinivasan A., Turbelidze G., Gould C.V., Arduino M.J., Sasisekharan R. Outbreak of adverse reactions associated with contaminated heparin. N. Engl. J. Med. 2008, 359:2674-2684.
6. Brunton L.L., Lazo J.S., Parker K.L. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2005, McGraw-Hill, New York, pp. 1470.
7. European Pharmacopoeia Commission, European Pharmacopeia Heparin Calcium, Optical Rotation 2008, Council of Europe, Strasbourg, pp. 34-35.
8. European Pharmacopoeia Commission, European Pharmacopeia Microdetermination of Water 2008, Council of Europe, Strasbourg, pp. 184-185.
9. European Pharmacopoeia Commission, European Pharmacopeia Heparin Calcium, Heparin Sodium 2008, Council of Europe, Strasbourg, pp. 2755-2757.
10. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., Capila I., Lansing J.C., Guglieri S., Fraser B., Al-Hakim A., Sibel Gunay N., Zhang Z., Robinson L., Buhse L., Nasr M., Woodcock J., Langer R., Venkataraman G., Linhardt R.J., Casu B., Torri G., Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol. 2008, 26:669-675.
11. Guerrini M., Zhang Z., Shriver Z., Naggi A., Masuko S., Langer R., Casu B., Linhardt R.J., Torri G., Sasisekharan R. Orthogonal analytical approaches to detect potential contaminants in heparin. Proc. Nat. Acad. Sci. U.S.A. 2009, 106:16956-16961.
12. Guerrini M., Shriver Z., Naggi A., Casu B., Linhardt R.J., Torri G., Sasisekharan R. Reply to oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nat. Biotechnol. 2010, 28:207-211.
13. Jolliffe I.T. Principal Component Analysis 2002, Springer Verlag, New York.
14. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., Lansing J.C., Srianganathan N., Zhao G., Galcheva-Gargova Z., Al-Hakim A., Bailey G.S., Fraser B., Roy S., Rogers-Cotrone T., Buhse L., Whary M., Fox J., Nasr M., Pan G.J.D., Shriver Z., Langer R.S., Venkataraman G., Austen K.F., Woodcock J., Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Eng. J. Med. 2008, 358:2457-2467.
15. Krzanowski W.J. Cross-validation in principal component analysis. Biometrics 1987, 43:575-584.
16. Maruyama T., Toida T., Imanari T., Yu G., Linhardt R.J. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr. Res. 1998, 306:35-43.
17. 1H NMR. Pharmeuropa Biol. 2008, 1:31-39.
18. Pan J., Qian Y., Zhou X., Pazandak A., Frazier S.B., Weiser P., Lu H., Zhang L. Oversulfated chondroitin sulfate is not the sole contaminant in heparin. Nat. Biotechnol. 2010, 28:203-207.
19. Perlin A.S., Sauriol F., Cooper B., Folkman J. Dermatan sulfate in pharmaceutical heparins. Thromb. Haemost. 1987, 58:792.
20. Toida T., Maruyama T., Ogita Y., Suzuki A., Toyoda H., Imanari T., Linhardt R.J. Preparation and anticoagulant activity of fully O-sulphonated glycosaminoglycans. Int. J. Biol. Macromol. 1999, 26:233-241.